Related Experiment Video

Updated: Jun 10, 2026

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor efficacy

T Cherry1, S L Longo, Z Tovar-Spinoza

  • 1Department of Neurosurgery, State University of New York (SUNY), Upstate Medical University, Syracuse, NY 13210, USA.

Gene Therapy
|July 29, 2010
PubMed

Insights

New hypoxia-activated oncolytic adenoviruses (Ads) demonstrate enhanced tumor-killing ability. These improved HIF-Ads show greater replication and antitumor efficacy compared to previous HYPR-Ads, offering a promising cancer therapy advancement.

Area of Science:

  • Oncolytic virotherapy
  • Cancer gene therapy
  • Adenovirus engineering

Background:

  • Oncolytic adenoviruses (Ads) show promise for cancer treatment by selectively targeting tumor cells.
  • Existing HYPR-Ads, activated by hypoxia-inducible factor (HIF), exhibit limitations in replication and overall antitumor activity.
  • There is a critical need for more potent oncolytic Ads with improved therapeutic efficacy.

Purpose of the Study:

  • To engineer novel HIF-activated oncolytic Ads (HIF-Ads) with enhanced replication and antitumor activity.
  • To overcome the limitations of first-generation HYPR-Ads.
  • To evaluate the therapeutic potential of modified HIF-Ads, including HIF-Ad-IL4.

Main Methods:

  • Development of HIF-Ads with a modified HIF-responsive promoter for E1A gene regulation and inclusion of the E3 gene region.
  • Assessment of conditional E1A expression under hypoxic conditions.
  • Evaluation of hypoxia-dependent replication, oncolytic activity, cellular release, and antitumor efficacy in preclinical models.

Main Results:

  • HIF-Ads demonstrated conditional E1A expression, hypoxia-dependent replication, and enhanced oncolytic and cellular release activities compared to HYPR-Ads.
  • HIF-Ads exhibited significantly greater potent antitumor efficacy than HYPR-Ads.
  • HIF-Ad-IL4 treatment resulted in substantial tumor regression (70%) and extensive leukocyte infiltration, showing up to six-fold greater efficacy than HYPR-Ads, HIF-Ad, and wild-type Ad.

Conclusions:

  • Treatment with engineered HIF-activated oncolytic Ads leads to measurable therapeutic responses and significant tumor regression.
  • The novel design of HIF-Ads represents a substantial improvement over first-generation oncolytic Ads.
  • HIF-Ads possess great potential for increasing the efficacy of oncolytic virotherapy in cancer treatment.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...